Sunday, September 2, 2018

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Expected to Witness a Sustainable Growth over 2018-2025 - QY Research

QYRlogo
This report studies the Bile Duct Cancer (Cholangiocarcinoma) Treatment market size by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Bile duct is a network of tube that connects the liver to the gall bladder. Bile duct carries a fluid called bile which is synthesize in the liver and stored in the gall bladder. The primary function of bile is breakdown of fats during digestion. Bile duct cancer is commonly known as cholangiocarcinoma. The particular cause of bile duct cancer is unknown but few factors that are responsible for developing bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in bile duct such as cysts, infection with liver flukes parasite that causes infection in bile duct leading to cancer, and exposure to harmful chemicals and toxins. Major symptoms associated with bile duct cancer includes jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever.

The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market.

The market for bile duct cancer treatment is growing at healthy CAGR across the globe owing to rising incidence and prevalence of bile duct cancer across the globe.

Moreover, the significant market growth has been observed in developing regions of Asia-pacific and Middle Eastern regions owing to common parasitic infection of the bile duct in these regions. For instance, according to The Cholangiocarcinoma Foundation, About 6,000 people in the United States develop bile duct cancer each year and Bile duct cancer is much more common in Asia and the Middle East, mostly because of a common parasitic infection of the bile duct.

This report focuses on the global top players, covered

    Accord Healthcare

    Bristol-Myers Squibb Company

    Celgene Corporation

    Delcath Systems

    Eli Lilly and Company

  1. Hoffman-La Roche
    Fresenius Kabi

    Johnson & Johnson Services

    Kyowa Hakko Kirin

    Mylan

    Novartis

    Pfizer

    Sanofi

    Teva Pharmaceuticals Industries

Market segment by Regions/Countries, this report covers

    North America

    Europe

    China

    Rest of Asia Pacific

    Central & South America

    Middle East & Africa

Market segment by Type, the product can be split into

    Drug Therapy

    Radiation Therapy

    Surgery

Market segment by Application, the market can be split into

    Intrahepatic Bile Duct Cancer

    Extrahepatic Bile Duct Cancer

The study objectives of this report are:

    To study and forecast the market size of Bile Duct Cancer (Cholangiocarcinoma) Treatment in global market.

    To analyze the global key players, SWOT analysis, value and global market share for top players.

    To define, describe and forecast the market by type, end use and region.

    To analyze and compare the market status and forecast among global major regions.

    To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

    To identify significant trends and factors driving or inhibiting the market growth.

    To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

    To strategically analyze each submarket with respect to individual growth trend and their contribution to the market

    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in

Request Sample Report 
and TOC@ https://www.qyresearch.com/index/detail/699567/global-bile-duct-cancer-cholangiocarcinoma-treatment-market
About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.

QY Research Achievements:  

Year of Experience: 11 Years

Consulting Projects: 500+ successfully conducted so far

Global Reports: 5000 Reports Every Years

Resellers Partners for Our Reports: 150 + Across Globe

Global Clients: 34000+

Contact US

QY Research, INC.

Tina

17890 Castleton, Suite 218,

City of industry, CA – 91748

USA: +1 626 295 2442

Email: sales@qyrsearchglobal.com

Web: www.qyresearchglobal.com

For other region, contact number given below

+86 108 294 5717 Beijing

+852 3062 8839 HK

No comments: